172 related articles for article (PubMed ID: 36714137)
21. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Robinson M; Horn J
Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
[TBL] [Abstract][Full Text] [Related]
23. Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database.
Watanabe A; Momo K; Tanaka K; Uchikura T; Kiryu Y; Niiyama K; Kodaira N; Matsuzaki A; Sasaki T
Biol Pharm Bull; 2022; 45(9):1373-1377. PubMed ID: 36047207
[TBL] [Abstract][Full Text] [Related]
24. Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Papp LA; Hancu G; Kelemen H; Tóth G
Electrophoresis; 2021 Sep; 42(17-18):1761-1789. PubMed ID: 34004039
[TBL] [Abstract][Full Text] [Related]
25. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Zheng RN
World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
[TBL] [Abstract][Full Text] [Related]
27. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
29. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
30. Impact of proton pump inhibitors on cytochrome P450 activity assessed by
Rocco A; Compare D; Sgamato C; Coccoli P; Chiodini P; Nardone G
Aliment Pharmacol Ther; 2021 Mar; 53(5):608-615. PubMed ID: 33368499
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
32. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
33. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial.
Kim JS; Seo SI; Kang SH; Lee SK; Kim AR; Park HW; Kim BT; Song GS
J Neurogastroenterol Motil; 2023 Jan; 29(1):58-64. PubMed ID: 36581325
[TBL] [Abstract][Full Text] [Related]
34. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Thomson AB
Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
[TBL] [Abstract][Full Text] [Related]
35. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
36. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function.
Son M; Park IS; Kim S; Ma HW; Kim JH; Kim TI; Kim WH; Han J; Kim SW; Cheon JH
Front Immunol; 2022; 13():870817. PubMed ID: 35693794
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
38. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Park CH; Kim EH; Roh YH; Kim HY; Lee SK
PLoS One; 2014; 9(11):e112558. PubMed ID: 25394217
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution.
Mouly S; Charlemagne A; Lejeunne P; Fagnani F
Curr Ther Res Clin Exp; 2009 Aug; 70(4):282-98. PubMed ID: 24683238
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
